Online Exclusive

T-Cell Receptor Diversity May Be Key to Treatment of Follicular Lymphoma

Healthy white blood cells play a crucial role in how the body fights follicular lymphoma. That's according to the results of a study led by Mayo Clinic hematologists.

FDA Alert

Tinostamustine Granted Orphan Drug Designation for T-Cell Prolymphocytic Leukemia

The FDA has granted Orphan Drug Designation to tinostamustine, an alkylating deacetylase inhibiting molecule for the treatment of T-cell prolymphocytic leukemia.

Your Career Path

Patient Communication: The Do's & Don'ts of Delivering a Cancer Diagnosis

Hematologists/oncologists wear many hats and one of the most important aspects of their job is delivering bad news to their patients, specifically the initial diagnosis of cancer.

ASH 2018 Coverage

Microbiome Diversity Key to Survival After Allo-HCT

By Peter M. Goodwin

Overall survival after allo-HCT was found to be adversely influenced by a lack of diversity in the intestinal microbiota.

Personalized Prediction Model Improves Prognosis in Myelodysplastic Syndromes

By Mark L. Fuerst

A personalized, machine learning-based prediction model can help clinicians risk stratify patients with myelodysplastic syndromes.

Initial Data on Lisocabtagene Maraleucel in R/R Chronic Lymphocytic Leukemia

By Richard Simoneaux

Although the treatment of CLL has drastically changed over the past few years complete response rates remain low, thus necessitating the use of continuous therapy. 

From the Issue

Dasatinib, the first and only second-generation TKI approved for pediatric patients with newly diagnosed Ph+ ALL in combination with chemo, adds another important tool to a medical toolkit that had long been light on options.

Colleague Conversations

A Discussion About the Field of Hematology/Oncology

HemOnc Times caught up with Pamela Crilley, DO, and Praneeth Baratam, MD, to get perspectives on the field from a seasoned hematologist/oncologist as well as one at the beginning of his career.